Cypress Bioscience purchases PRP:
This article was originally published in Clinica
Cypress Bioscience (formerly Imre) is to acquire biopharmaceutical concern PRP, subject to shareholder approval and other conditions. Under the terms of the agreement, PRP will become a wholly-owned subsidiary of Cypress. Cypress, which is based in San Diego, manufactures medical devices and therapeutics for the treatment of certain immune disorders. Its leading product, the Prosorba column, is approved by the US FDA for use in the treatment of idiopathic thrombocytopenic purpura. The product is undergoing clinical trials for the treatment of rheumatoid arthritis. PRP produces agents to treat blood platelet disorders.